PT - JOURNAL ARTICLE AU - TAKAHIKO ITO AU - YOSHITAKA HONMA AU - HIDEKAZU HIRANO AU - HIROKAZU SHOJI AU - NATSUKO OKITA AU - SATORU IWASA AU - ATSUO TAKASHIMA AU - KEN KATO AU - NARIKAZU BOKU TI - S-1 Monotherapy After Failure of Platinum Plus 5-Fluorouracil Chemotherapy in Recurrent or Metastatic Esophageal Carcinoma AID - 10.21873/anticanres.13545 DP - 2019 Jul 01 TA - Anticancer Research PG - 3931--3936 VI - 39 IP - 7 4099 - http://ar.iiarjournals.org/content/39/7/3931.short 4100 - http://ar.iiarjournals.org/content/39/7/3931.full SO - Anticancer Res2019 Jul 01; 39 AB - Background/Aim: Platinum plus 5-fluorouracil (FP) is a first-line regimen of palliative chemotherapy for recurrent or metastatic esophageal squamous cell carcinoma (RM-ESCC). In this retrospective study, we evaluated the efficacy and safety of S-1 monotherapy as a salvage line treatment for RM-ESCC, focusing on the reasons for discontinuation of prior FP. Materials and Methods: The subjects of this study had RM-ESCC and received S-1 after failure of FP. Results: Eleven patients were enrolled. Nine patients were refractory and two were intolerant to prior FP. The median progression-free survival and overall survival time were 3.0 and 11.7 months, respectively. Overall response rate was 22.2% and disease control rate of the 11 patients was 36.4%. Median relative dose intensity of 5-FU was 100% (range=85-100%). Conclusion: S-1 efficacy in RM-ESCC when given after FP was modest. Favorable OS may be attributed to good local control rather than to the efficacy of S-1 monotherapy.